Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CWP-0403 (Anagliptin) in Type 2 Diabetes
NCT00888719Phase 2Completed
- Sponsor
- JW Pharmaceutical Corporation
- Start
- Feb 2009
- Primary completion
- Jan 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of anagliptin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by JW Pharmaceutical Corporation. Primary endpoint: Change in HbA1c at 12 weeks. Started Feb 2009; status: completed.
02
Drugs
anagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00888719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00888719.